Symtuza (darunavir + cobicistat + emtricitabine (FTC) + TAF)
- Symtuza is a fixed dose combination that contains darunavir, cobicistat, emtricitabine and tenofovir alafenamide.
- Standard dose is to take one pill once-daily.
- Symtuza needs to be taken with food.
Symtuza is approved for adults and adolescents (aged 12 years and older with body weight at least 40 kg).
Each film-coated tablet contains 800 mg of darunavir (as ethanolate), 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide (as fumarate).
- The most common side effects (occurring in more than 1 in 10 people) are diarrhoea, nausea (feeling sick), tiredness, headache and rash. For the full list of side effects please see the package leaflet.
- Symtuza was approved in Europe in September 2017,
Please see details of individual drugs (linked above) for details of side effects and the links to the patient information and product information at the link below for full prescribing details.
The European patient information and detailed Product Information for darunavir are available in PDF format from this link at the European Medicines Agency (EMA) website.
The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.
The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.